In contrast to other reversible inhibitors such as gefitinib or erlotinib, DCN has a pan-HER inhibition profile by simultaneously inhibiting EGFR, HER2 and HER4, resulting in its better clinical efficacy in non-small cell lung cancers (NSCLC) with activating EGFR mutations.24 However, in addition to its classical enzymatic pathway, it is manifest, from recent evidences, that DCN might also interact with non-canonical targets, namely DNA, where it binds non-covalently to the minor grooves. This evidence concerns the gene EGFR and non-small cell lung carcinoma.